国际抗衰服务管理中心旗舰店

新冠催人老！大脑变老20岁，智商下降10点，69%患者肾损伤，我该怎么办？

2023年01月10日

疫情全面放开，多数人都得走一遭“阳关道”，笔者也在距“决赛圈”遥遥无期的第一轮，就倒了下去。

转阴后，身体似乎发生了点改变：脑子晕乎乎，咳嗽没停过，走路大喘气，心跳砰砰砰......

浑身上下，从里到外，哪都不对劲，似乎身体的时钟被拨得更快了。

但很不幸，这不仅只是“感觉”。中山大学的研究人员们发现，感染新冠真的会加速人体生理年龄——让你老得更快[1]。

为何新冠感染会加速衰老？对此，我们又该如何应对？

今天，我们就来聊聊新冠病毒对人体，如大脑、肾脏、心脏等多个重要组织器官的影响，并综合当下权威科学研究，看看“我们该怎么办”。

疫情中，“新冠病毒对人类大脑的影响”，几度登上热榜、引发讨论。

去年3月，牛津大学研究团队于国际顶级期刊Nature发文，在分析权威生物样本库UK Biobank中多达785名患者数据后发现，感染新冠会让人类与嗅觉、记忆相关的脑区发生退行性变化，程度相当于大脑提前老化约10岁[2]。

图注：新冠感染与大脑结构变化有关

甚至，领域内专家在评估研究后表示：研究总体证据充足、可靠，可以支撑结论，尽管这个结论不是我们想看到的。

仅2月后，医学圣刊《柳叶刀》子刊又再发文，报道新冠重症导致的认知障碍，几乎等同50至70岁间发生的自然认知衰退，意味大脑足足老了20岁，智商下降10点！[3]

并且，这一影响在半年后仍然存在[3]。

图注：新冠重症患者认知丧失与痴呆程度，以及与年龄间的比较

目前，因新冠感染加速人类脑衰老的科学证据已很充分：从大脑微观结构特征改变[4, 5]，到认知、复杂事务处理能力下降[6-8]，以及中风、痴呆症等关联疾病发生率上升[9, 10]。

干预手段

大脑要想好利索，花费的时间远比清除新冠病毒要久得多[9]。帮助大脑恢复，下面几种补充剂大有可为。

No.1

木犀草素——治疗嗅觉丧失，缓解认知障碍

人体临床证实，木犀草素联用棕榈酰乙醇酰胺（PEA），1月后嗅觉明显改善[11]，3月后多数人嗅觉可完全恢复[12]。

同时，木犀草素也能通过减少神经炎症发挥缓解认知功能障碍的功效[11]。

用法：每天700 mg PEA +70 mg木犀草素，可早餐前5-10分钟舌下含服[13]。

No.2

ω-3脂肪酸——改善认知，调节情绪

人体临床证实，ω-3脂肪酸能有效抑制慢性炎症、恢复组织稳态，对情绪和神经认知障碍的治疗具有积极作用[14]。

用法：建议每天至少摄入0.5 g ω-3脂肪酸[14]，可通过饮食与补充剂（如鱼油）实现。

西医中重要的排泄器官，中医里贮精纳气之所，养护肾脏，是不少抗衰养生人士的心头好。然新冠又向我们砸来了冰冷的数据：新冠感染引发的肾损伤可能会达到69%！[15]

其实，从疫情初始，新冠病毒与肾衰竭间的关联就已经被发现，“急性肾损伤”目前也已被纳入《新冠感染诊治专家共识》，成为新冠病毒重要的并发症之一[16]。

新冠病毒如何危害我们的肾脏？

综合目前研究证据，新冠病毒能通过直接侵入肾脏导致器官纤维化[17]、激活炎症风暴[18]、横纹肌溶解[19]等多方面影响肾脏健康。

例如，当研究人员用病毒直接感染人类诱导多能干细胞衍生的类肾脏器官，发现新冠病毒能够直接附着、感染肾脏诱导细胞损伤，且随后造成了器官纤维化[17]。

干预手段

感染新冠的患者即使康复，出现肾病的风险仍然会增加[20]。

为肾脏恢复“加把力”，我们可以尝试摄入NAD+前体，每日2g NR或相应水平NMN，即可发挥不错的功效[21]。

除了补充NAD+前体外，前文提到可改善大脑认知的ω-3脂肪酸，同样在人体临床中被证实可改善重症患者病肾功能[22]。

在更名前，新冠感染一直以“新型冠状肺炎”而为人知，且“肺部CT”变化也是疾病确诊的重要标志。

尽管病毒不断变异，已从原始毒株转入奥密克戎时代，但新冠感染对肺部的损伤仍然存在.不少人在感染病毒后，不同程度出现肺部炎，甚至“白肺”现象。

2022年7月，一项由东京大学、京都大学联合多家科研单位联合发布的研究显示，在奥密克戎的庞大家族分支里，BA.5分支能感染肺泡细胞，可能重新“找回了”入肺能力[23]。

这或许也部分解释了“为何奥密克戎仍可能让人体出现肺部感染”的现象。

干预手段

经系统检索，我们为大家筛选出以下有助于肺部损伤改善的物质：

No.1

芹菜素

动物实验证实，口服芹菜素能够改善肺部炎症[24]、纤维化过程[25]，以及减轻呼吸道炎症[26]。

No.2

乙酰半胱氨酸（NAC）

动物模型验证，NAC可缓解新冠导致的肺损伤、呼吸困难等情况[27]，并能缓解药物扑热息痛过量使用的不适及改善新冠康复后的咳嗽症状[28]。

感染新冠病毒后，除了发烧、咳嗽，心慌心悸、心律失常也是不少人都有过的感受。

德国一项针对百名成年新冠康复者的统计表明，60%的人被发现有持续的心肌炎症，78%人群在确诊两个多月后表现出轻度或中度心脏损害[29]。

目前已发现新冠与心力衰竭、运动耐量受损、心律失常和心源性猝死[30]的潜在关联。

干预手段

在预防或改善心肌损伤上，笔者综合科研证据与亲身经历，向大家推荐有“万金油”之称的辅酶Q10。

人体临床研究回顾表明，每天服用3次10mg辅酶Q10和20mg曲美他嗪，持续2周，患者心肌炎症状就能得到显著改善[31]。

看到这里，你以为就完了？

噩耗是，新冠感染对组织器官的负面影响，还远没有结束。

集时光派全体编辑之力，我们还发现：

嗳气、腹痛、便秘、呕吐，即使你以前是“钢铁肠胃”，阳了后，都可能感受一遍[32, 33]。

丧失味觉、饭居然是苦的……将近三分之一的患者在症状出现后的7个月，依然存在味觉和嗅觉障碍[34]。

眼睛疼、看不清东西、视力下降，基本上每4个新冠患者中便会有1位[35]。

“没感觉”，“那方面好像不行了”。报道中，男性新冠患者因生殖系统影响而困惑的呼声，时有耳闻[36]。

愿我们向阳而生，既不因感染新冠加速衰老，也能健康平安行在抗衰征途上。

国际抗衰服务管理中心

参考文献

[1] Cao, X., Li, W., Wang, T., Ran, D., Davalos, V., & Planas-Serra, L. et al. (2022). Accelerated biological aging in COVID-19 patients. Nature Communications, 13(1). doi: 10.1038/s41467-022-29801-8

[2] Douaud, G., Lee, S., Alfaro-Almagro, F., Arthofer, C., Wang, C., McCarthy, P., Lange, F., Andersson, J. L. R., Griffanti, L., Duff, E., Jbabdi, S., Taschler, B., Keating, P., Winkler, A. M., Collins, R., Matthews, P. M., Allen, N., Miller, K. L., Nichols, T. E., & Smith, S. M. (2022). SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature, 604(7907), 697–707. https://doi.org/10.1038/s41586-022-04569-5

[3] Hampshire, A., Chatfield, D. A., MPhil, A. M., Jolly, A., Trender, W., Hellyer, P. J., Giovane, M. D., Newcombe, V. F. J., Outtrim, J. G., Warne, B., Bhatti, J., Pointon, L., Elmer, A., Sithole, N., Bradley, J., Kingston, N., Sawcer, S. J., Bullmore, E. T., Rowe, J. B., Menon, D. K., … Cambridge NeuroCOVID Group, the NIHR COVID-19 BioResource, and Cambridge NIHR Clinical Research Facility (2022). Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort. EClinicalMedicine, 47, 101417. https://doi.org/10.1016/j.eclinm.2022.101417

[4] Lu, Y., Li, X., Geng, D., Mei, N., Wu, P. Y., Huang, C. C., Jia, T., Zhao, Y., Wang, D., Xiao, A., & Yin, B. (2020). Cerebral Micro-Structural Changes in COVID-19 Patients - An MRI-based 3-month Follow-up Study. EClinicalMedicine, 25, 100484. https://doi.org/10.1016/j.eclinm.2020.100484

[5] Mavrikaki, M., Lee, J., Solomon, I., & Slack, F. (2022). Severe COVID-19 is associated with molecular signatures of aging in the human brain. Nature Aging, 2(12), 1130-1137. doi: 10.1038/s43587-022-00321-w

[6] Mazza, M. G., Palladini, M., De Lorenzo, R., Magnaghi, C., Poletti, S., Furlan, R., Ciceri, F., COVID-19 BioB Outpatient Clinic Study group, Rovere-Querini, P., & Benedetti, F. (2021). Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain, behavior, and immunity, 94, 138–147. https://doi.org/10.1016/j.bbi.2021.02.021

[7] Zhao, S., Shibata, K., Hellyer, P., Trender, W., Manohar, S., Hampshire, A., & Husain, M. (2022). Rapid vigilance and episodic memory decrements in COVID-19 survivors. Brain Communications, 4(1). doi: 10.1093/braincomms/fcab295

[8] Davis, H., Assaf, G., McCorkell, L., Wei, H., Low, R., & Re'em, Y. et al. (2021). Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. Eclinicalmedicine, 38, 101019. doi: 10.1016/j.eclinm.2021.101019

[9] Taquet, M., Sillett, R., Zhu, L., Mendel, J., Camplisson, I., Dercon, Q., & Harrison, P. (2022). Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. The Lancet Psychiatry, 9(10), 815-827. doi: 10.1016/s2215-0366(22)00260-7

[10] Taquet, M., Geddes, J., Husain, M., Luciano, S., & Harrison, P. (2021). 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. The Lancet Psychiatry, 8(5), 416-427. doi: 10.1016/s2215-0366(21)00084-5

[11] De Luca, P., Camaioni, A., Marra, P., Salzano, G., Carriere, G., Ricciardi, L., Pucci, R., Montemurro, N., Brenner, M. J., & Di Stadio, A. (2022). Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study. Cells, 11(16), 2552. https://doi.org/10.3390/cells11162552

[12] Di Stadio, A., D'Ascanio, L., Vaira, L. A., Cantone, E., De Luca, P., Cingolani, C., Motta, G., De Riu, G., Vitelli, F., Spriano, G., De Vincentiis, M., Camaioni, A., La Mantia, I., Ferreli, F., & Brenner, M. J. (2022). Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo- Controlled Clinical Trial. Current neuropharmacology, 20(10), 2001–2012. https://doi.org/10.2174/1570159X20666220420113513

[13] Di Stadio, A., D'Ascanio, L., Vaira, L. A., Cantone, E., De Luca, P., Cingolani, C., Motta, G., Bartlett, J. A., & van der Voort Maarschalk, K. (2012). Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine. AAPS PharmSciTech, 13(4), 1110–1115. https://doi.org/10.1208/s12249-012-9839-7

[14] Yang, C. P., Chang, C. M., Yang, C. C., Pariante, C. M., & Su, K. P. (2022). Long COVID and long chain fatty acids (LCFAs): Psychoneuroimmunity implication of omega-3 LCFAs in delayed consequences of COVID-19. Brain, behavior, and immunity, 103, 19–27. https://doi.org/10.1016/j.bbi.2022.04.001

[15] Kris-Etherton, P. M., Harris, W. S., Appel, L. J., & AHA Nutrition Committee. American Heart Association (2003). Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arteriosclerosis, thrombosis, and vascular biology, 23(2), 151–152. https://doi.org/10.1161/01.atv.0000057393.97337.ae

[16] Aggarwal, S., Garcia-Telles, N., Aggarwal, G., Lavie, C., Lippi, G., & Henry, B. M. (2020). Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis (Berlin, Germany), 7(2), 91–96. https://doi.org/10.1515/dx-2020-0046

[17] 中华医学会肾脏病学分会专家组. 新型冠状病毒感染合并急性肾损伤诊治专家共识. 中华肾脏病杂志,2020,36 (03): 242-246. DOI: 10.3760/cma.j.cn441217-20200222-00035

[18] Jansen, J., Reimer, K. C., Nagai, J. S., Varghese, F. S., Overheul, G. J., de Beer, M., Roverts, R., Daviran, D., Fermin, L. A. S., Willemsen, B., Beukenboom, M., Djudjaj, S., von Stillfried, S., van Eijk, L. E., Mastik, M., Bulthuis, M., Dunnen, W. D., van Goor, H., Hillebrands, J. L., Triana, S. H., … Kramann, R. (2022). SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids. Cell stem cell, 29(2), 217–231.e8. https://doi.org/10.1016/j.stem.2021.12.010

[19] Montazersaheb, S., Hosseiniyan Khatibi, S., Hejazi, M., Tarhriz, V., Farjami, A., & Ghasemian Sorbeni, F. et al. (2022). COVID-19 infection: an overview on cytokine storm and related interventions. Virology Journal, 19(1). doi: 10.1186/s12985-022-01814-1

[20] Taxbro, K., Kahlow, H., Wulcan, H., & Fornarve, A. (2020). Rhabdomyolysis and acute kidney injury in severe COVID-19 infection. BMJ Case Reports, 13(9), e237616. doi: 10.1136/bcr-2020-237616

[21] Bowe, B., Xie, Y., Xu, E., & Al-Aly, Z. (2021). Kidney Outcomes in Long COVID. Journal of the American Society of Nephrology : JASN, 32(11), 2851–2862. https://doi.org/10.1681/ASN.2021060734

[22] Altay, O., Arif, M., Li, X., Yang, H., Aydın, M., Alkurt, G., Kim, W., Akyol, D., Zhang, C., Dinler-Doganay, G., Turkez, H., Shoaie, S., Nielsen, J., Borén, J., Olmuscelik, O., Doganay, L., Uhlén, M., & Mardinoglu, A. (2021). Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 8(17), e2101222. https://doi.org/10.1002/advs.202101222

[23] Doaei, S., Gholami, S., Rastgoo, S., Gholamalizadeh, M., Bourbour, F., Bagheri, S. E., Samipoor, F., Akbari, M. E., Shadnoush, M., Ghorat, F., Mosavi Jarrahi, S. A., Ashouri Mirsadeghi, N., Hajipour, A., Joola, P., Moslem, A., & Goodarzi, M. O. (2021). The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial. Journal of translational medicine, 19(1), 128. https://doi.org/10.1186/s12967-021-02795-5

[24] https://mainichi.jp/english/articles/20220708/p2a/00m/0sc/026000c

[25] Cardenas, H., Arango, D., Nicholas, C., Duarte, S., Nuovo, G. J., He, W., Voss, O. H., Gonzalez-Mejia, M. E., Guttridge, D. C., Grotewold, E., & Doseff, A. I. (2016). Dietary Apigenin Exerts Immune-Regulatory Activity in Vivo by Reducing NF-κB Activity, Halting Leukocyte Infiltration and Restoring Normal Metabolic Function. International journal of molecular sciences, 17(3), 323. https://doi.org/10.3390/ijms17030323

[26] Chen, L., & Zhao, W. (2016). Apigenin protects against bleomycin-induced lung fibrosis in rats. Experimental and therapeutic medicine, 11(1), 230–234. https://doi.org/10.3892/etm.2015.2885

[27] Pang, L., Zou, S., Shi, Y., Mao, Q., & Chen, Y. (2019). Apigenin attenuates PM2.5-induced airway hyperresponsiveness and inflammation by down-regulating NF-κB in murine model of asthma. International journal of clinical and experimental pathology, 12(10), 3700–3709.

[28] de Alencar, J. C. G., Moreira, C. L., Müller, A. D., Chaves, C. E., Fukuhara, M. A., da Silva, E. A., Miyamoto, M. F. S., Pinto, V. B., Bueno, C. G., Lazar Neto, F., Gomez Gomez, L. M., Menezes, M. C. S., Marchini, J. F. M., Marino, L. O., Brandão Neto, R. A., Souza, H. P., & COVID Register Group (2021). Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 72(11), e736–e741. https://doi.org/10.1093/cid/ciaa1443

[29] Tenório, M. C. D. S., Graciliano, N. G., Moura, F. A., Oliveira, A. C. M., & Goulart, M. O. F. (2021). N-Acetylcysteine (NAC): Impacts on Human Health. Antioxidants (Basel, Switzerland), 10(6), 967. https://doi.org/10.3390/antiox10060967

[30] Puntmann, V., Carerj, M., Wieters, I., Fahim, M., Arendt, C., & Hoffmann, J. et al. (2020). Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiology, 5(11), 1265. doi: 10.1001/jamacardio.2020.3557

[31] Becker, R. (2020). Anticipating the long-term cardiovascular effects of COVID-19. Journal Of Thrombosis And Thrombolysis, 50(3), 512-524. doi: 10.1007/s11239-020-02266-6

Yin, Y. J., Zeng, S. L., Li, Y. W., Wu, Z., Huang, D. J., & Tang, H. Z. (2021). The effect of coenzyme [30] Becker, R. (2020). Anticipating the long-term cardiovascular effects of COVID-19. Journal Q10 plus trimetazidine on acute viral myocarditis treatment. American journal of translational research, 13(12), 13854–13861.

[32] Weng, J., Li, Y., Li, J., Shen, L., Zhu, L., & Liang, Y. et al. (2021). Gastrointestinal sequelae 90 days after discharge for COVID-19. The Lancet Gastroenterology &Amp; Hepatology, 6(5), 344-346. doi: 10.1016/s2468-1253(21)00076-5

[33] Bogariu, A., & Dumitrascu, D. (2021). Digestive involvement in Long- COVID syndrome. Medicine And Pharmacy Reports. doi: 10.15386/mpr-2340

[34] Nguyen, N., Hoang, V., Lagier, J., Raoult, D., & Gautret, P. (2021). Long-term persistence of olfactory and gustatory disorders in COVID-19 patients. Clinical Microbiology And Infection, 27(6), 931-932. doi: 10.1016/j.cmi.2020.12.021

[35] Jeong, G., Kwon, H., Ng, W., Liu, X., Moon, H., & Yoon, G. et al. (2022). Ocular tropism of SARS-CoV-2 in animal models with retinal inflammation via neuronal invasion following intranasal inoculation. Nature Communications, 13(1). doi: 10.1038/s41467-022-35225-1

[36] Chu, K., Nackeeran, S., Horodyski, L., Masterson, T., & Ramasamy, R. (2021). COVID-19 Infection Is Associated With New Onset Erectile Dysfunction: Insights From a National Registry. Sexual Medicine, 10(1), 100478-1. doi: 10.1016/j.esxm.2021.100478

0阅读 0赞

国际抗衰服务管理中心